Peng Men

553 total citations
29 papers, 371 citations indexed

About

Peng Men is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Oncology. According to data from OpenAlex, Peng Men has authored 29 papers receiving a total of 371 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Endocrinology, Diabetes and Metabolism, 6 papers in Molecular Biology and 6 papers in Oncology. Recurrent topics in Peng Men's work include Diabetes Treatment and Management (11 papers), Diabetes Management and Research (6 papers) and Metabolism, Diabetes, and Cancer (4 papers). Peng Men is often cited by papers focused on Diabetes Treatment and Management (11 papers), Diabetes Management and Research (6 papers) and Metabolism, Diabetes, and Cancer (4 papers). Peng Men collaborates with scholars based in China, Germany and United Kingdom. Peng Men's co-authors include Suodi Zhai, Rongsheng Zhao, Xin Liu, Na He, Chunli Song, Yuhui Wang, Chaojie Liu, Zhigang Zhao, Shuli Qu and Huilin Tang and has published in prestigious journals such as PLoS ONE, Medicine and Osteoporosis International.

In The Last Decade

Peng Men

27 papers receiving 363 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peng Men China 12 111 76 72 70 57 29 371
Karen Sheehy Australia 6 193 1.7× 97 1.3× 95 1.3× 92 1.3× 67 1.2× 6 527
Murali Munisamy India 12 42 0.4× 26 0.3× 47 0.7× 111 1.6× 42 0.7× 35 405
Marshall Sack United States 11 48 0.4× 122 1.6× 27 0.4× 88 1.3× 42 0.7× 12 517
Joaquim Barreto Brazil 11 139 1.3× 35 0.5× 31 0.4× 99 1.4× 87 1.5× 35 406
Karina Soto Portugal 10 83 0.7× 21 0.3× 58 0.8× 93 1.3× 73 1.3× 22 481
Zhiquan Wang China 12 63 0.6× 41 0.5× 118 1.6× 71 1.0× 97 1.7× 29 468
Issam S. Hamadeh United States 15 42 0.4× 68 0.9× 110 1.5× 117 1.7× 39 0.7× 39 698
Kumiko Hamano Japan 10 109 1.0× 42 0.6× 16 0.2× 170 2.4× 52 0.9× 20 456

Countries citing papers authored by Peng Men

Since Specialization
Citations

This map shows the geographic impact of Peng Men's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peng Men with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peng Men more than expected).

Fields of papers citing papers by Peng Men

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peng Men. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peng Men. The network helps show where Peng Men may publish in the future.

Co-authorship network of co-authors of Peng Men

This figure shows the co-authorship network connecting the top 25 collaborators of Peng Men. A scholar is included among the top collaborators of Peng Men based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peng Men. Peng Men is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wang, Chao, Peng Men, Ruixia Zhang, et al.. (2025). Efficacy, safety and cost-effectiveness of obinutuzumab in patients with follicular lymphoma: a rapid review. Frontiers in Pharmacology. 15. 1426772–1426772.
2.
3.
Qiu, Tingting, et al.. (2021). Cost-Effectiveness of Aprepitant in Preventing Chemotherapy-Induced Nausea and Vomiting: A Systematic Review of Published Articles. Frontiers in Public Health. 9. 660514–660514. 5 indexed citations
4.
Men, Peng, et al.. (2021). Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China. Cost Effectiveness and Resource Allocation. 19(1). 46–46. 9 indexed citations
5.
6.
7.
Salem, Ahmed, et al.. (2021). Cost–effectiveness analysis of empagliflozin compared with glimepiride in patients with Type 2 diabetes in China. Journal of Comparative Effectiveness Research. 10(6). 469–480. 4 indexed citations
8.
9.
10.
Men, Peng, et al.. (2020). <p>Empagliflozin in Type 2 Diabetes Mellitus Patients with High Cardiovascular Risk: A Model-Based Cost-Utility Analysis in China</p>. Diabetes Metabolic Syndrome and Obesity. Volume 13. 2823–2831. 12 indexed citations
11.
12.
Liu, Xin, Peng Men, Bo Wang, Gaojun Cai, & Zhigang Zhao. (2019). Effect of dipeptidyl-peptidase-4 inhibitors on C-reactive protein in patients with type 2 diabetes: a systematic review and meta-analysis. Lipids in Health and Disease. 18(1). 144–144. 16 indexed citations
13.
Luo, Qiuhua, Peng Men, Zhiyong Liu, Suodi Zhai, & Mingyan Jiang. (2019). Is De-escalated Bisphosphonates Therapy a Suitable Alternative to Standard Dosing in Malignant Tumor Patients With Bone Metastases: A Systematic Review and Meta-Analysis. Frontiers in Oncology. 9. 774–774. 4 indexed citations
14.
Men, Peng, Xiaotong Li, Huilin Tang, & Suodi Zhai. (2018). Efficacy and safety of saxagliptin in patients with type 2 diabetes: A systematic review and meta-analysis. PLoS ONE. 13(5). e0197321–e0197321. 25 indexed citations
15.
16.
17.
Men, Peng, Na He, Chunli Song, & Suodi Zhai. (2017). Dipeptidyl peptidase-4 inhibitors and risk of arthralgia: A systematic review and meta-analysis. Diabetes & Metabolism. 43(6). 493–500. 25 indexed citations
18.
Liu, Xin, Peng Men, Yuhui Wang, et al.. (2017). Efficacy and Safety of Lomitapide in Hypercholesterolemia. American Journal of Cardiovascular Drugs. 17(4). 299–309. 21 indexed citations
19.
Liu, Xin, Peng Men, Yuhui Wang, Suodi Zhai, & Chaojie Liu. (2016). Impact of dipeptidyl peptidase-4 inhibitors on serum adiponectin: a meta-analysis. Lipids in Health and Disease. 15(1). 204–204. 24 indexed citations
20.
Li, Yali, Hui Jiang, Yanping Dong, et al.. (2015). Discovery, synthesis and biological evaluation of 2-(4-(N-phenethylsulfamoyl)phenoxy)acetamides (SAPAs) as novel sphingomyelin synthase 1 inhibitors. Bioorganic & Medicinal Chemistry. 23(18). 6173–6184. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Karen Sheehy Breakdown of academic impact, for papers by Murali Munisamy Breakdown of academic impact, for papers by Marshall Sack Breakdown of academic impact, for papers by Joaquim Barreto Breakdown of academic impact, for papers by Karina Soto Breakdown of academic impact, for papers by Zhiquan Wang Breakdown of academic impact, for papers by Issam S. Hamadeh Breakdown of academic impact, for papers by Kumiko Hamano
Rankless by CCL
2026